Cargando…

Geographical prevalence of SARS-CoV-2 variants, August 2020 to July 2021

We extracted one-year genomic data (August 2020–July 2021) from GISAID EpiCoV™ database and estimated monthly proportions of 11 SARS-CoV-2 variants in various geographical regions. From continental perspective, Delta VOC predominated in Africa, Asia, Europe, North America and Oceania, with proportio...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Wai Sing, Lam, Yuk Man, Law, Janet Hei Yin, Chan, Tsun Leung, Ma, Edmond Shiu Kwan, Tang, Bone Siu Fai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931783/
https://www.ncbi.nlm.nih.gov/pubmed/35304553
http://dx.doi.org/10.1038/s41598-022-08684-1
_version_ 1784671334958104576
author Chan, Wai Sing
Lam, Yuk Man
Law, Janet Hei Yin
Chan, Tsun Leung
Ma, Edmond Shiu Kwan
Tang, Bone Siu Fai
author_facet Chan, Wai Sing
Lam, Yuk Man
Law, Janet Hei Yin
Chan, Tsun Leung
Ma, Edmond Shiu Kwan
Tang, Bone Siu Fai
author_sort Chan, Wai Sing
collection PubMed
description We extracted one-year genomic data (August 2020–July 2021) from GISAID EpiCoV™ database and estimated monthly proportions of 11 SARS-CoV-2 variants in various geographical regions. From continental perspective, Delta VOC predominated in Africa, Asia, Europe, North America and Oceania, with proportions of 67.58–98.31% in July 2021. In South America, proportion of Delta VOC (23.24%) has been approaching the predominant yet diminishing Gamma VOC (56.86%). We further analyzed monthly data on new COVID-19 cases, new deaths, vaccination status and variant proportions of 6 countries. Delta VOC predominated in all countries except Brazil (Gamma VOC) in July 2021. In most occasions, rise and predominance of Alpha, Beta, Gamma, Delta and Zeta variants were accompanied with surges of new cases, especially after the time point of major lineage interchange. The ascending phases of new cases lasted for 1–5 months with 1.69- to 40.63-fold peak growth, whereas new death tolls varied with regional vaccination status. Our data suggested surges of COVID-19 cases might be predicted from variant surveillance data. Despite vaccine breakthroughs by Delta VOC, death tolls were more stable in countries with better immunization coverage. Another takeaway is the urgent need to improve vaccine efficacy against Delta and emerging variants.
format Online
Article
Text
id pubmed-8931783
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-89317832022-03-18 Geographical prevalence of SARS-CoV-2 variants, August 2020 to July 2021 Chan, Wai Sing Lam, Yuk Man Law, Janet Hei Yin Chan, Tsun Leung Ma, Edmond Shiu Kwan Tang, Bone Siu Fai Sci Rep Article We extracted one-year genomic data (August 2020–July 2021) from GISAID EpiCoV™ database and estimated monthly proportions of 11 SARS-CoV-2 variants in various geographical regions. From continental perspective, Delta VOC predominated in Africa, Asia, Europe, North America and Oceania, with proportions of 67.58–98.31% in July 2021. In South America, proportion of Delta VOC (23.24%) has been approaching the predominant yet diminishing Gamma VOC (56.86%). We further analyzed monthly data on new COVID-19 cases, new deaths, vaccination status and variant proportions of 6 countries. Delta VOC predominated in all countries except Brazil (Gamma VOC) in July 2021. In most occasions, rise and predominance of Alpha, Beta, Gamma, Delta and Zeta variants were accompanied with surges of new cases, especially after the time point of major lineage interchange. The ascending phases of new cases lasted for 1–5 months with 1.69- to 40.63-fold peak growth, whereas new death tolls varied with regional vaccination status. Our data suggested surges of COVID-19 cases might be predicted from variant surveillance data. Despite vaccine breakthroughs by Delta VOC, death tolls were more stable in countries with better immunization coverage. Another takeaway is the urgent need to improve vaccine efficacy against Delta and emerging variants. Nature Publishing Group UK 2022-03-18 /pmc/articles/PMC8931783/ /pubmed/35304553 http://dx.doi.org/10.1038/s41598-022-08684-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Chan, Wai Sing
Lam, Yuk Man
Law, Janet Hei Yin
Chan, Tsun Leung
Ma, Edmond Shiu Kwan
Tang, Bone Siu Fai
Geographical prevalence of SARS-CoV-2 variants, August 2020 to July 2021
title Geographical prevalence of SARS-CoV-2 variants, August 2020 to July 2021
title_full Geographical prevalence of SARS-CoV-2 variants, August 2020 to July 2021
title_fullStr Geographical prevalence of SARS-CoV-2 variants, August 2020 to July 2021
title_full_unstemmed Geographical prevalence of SARS-CoV-2 variants, August 2020 to July 2021
title_short Geographical prevalence of SARS-CoV-2 variants, August 2020 to July 2021
title_sort geographical prevalence of sars-cov-2 variants, august 2020 to july 2021
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931783/
https://www.ncbi.nlm.nih.gov/pubmed/35304553
http://dx.doi.org/10.1038/s41598-022-08684-1
work_keys_str_mv AT chanwaising geographicalprevalenceofsarscov2variantsaugust2020tojuly2021
AT lamyukman geographicalprevalenceofsarscov2variantsaugust2020tojuly2021
AT lawjanetheiyin geographicalprevalenceofsarscov2variantsaugust2020tojuly2021
AT chantsunleung geographicalprevalenceofsarscov2variantsaugust2020tojuly2021
AT maedmondshiukwan geographicalprevalenceofsarscov2variantsaugust2020tojuly2021
AT tangbonesiufai geographicalprevalenceofsarscov2variantsaugust2020tojuly2021